Citations

Clear

67 citation(s) found for "Taner, Burcin".

Radiologic Characterization of Ischemic Cholangiopathy in Donation-After-Cardiac-Death Liver Transplants and Correlation With Clinical Outcomes
Giesbrandt, Kirk J., Bulatao, Ilynn , Nguyen, Justin H. , Paz‐Fumagalli, Ricardo , Bulatao, Ilynn G, Taner, C. Burcin , Keaveny, Andrew P.

Mayo Clinic

American Journal of Roentgenology | October 24, 2015 | Volume: 205 | Issue: 5 | Pages: 976-984

10.2214/ajr.14.13383 | PMID 26496544 Get It

Patent foramen ovale in liver transplant recipients does not negatively impact short‐term outcomes
Werlang, Monia E., Palmer, William C. , Boyd, Evelyn , Cangemi, David J. , Harnois, Denise M. , Taner, Cemal Burcin, Stancampiano, Fernando F. , Boyd, Evelyn A, Taner, Cemal B, Stancampiano, Fernando F

Mayo Clinic

Clinical Transplantation | October 8, 2015 | Volume: 30 | Issue: 1 | Pages: 26-32

10.1111/ctr.12643 | PMID 26448343 Get It

AbstractAimPatent foramen ovale (PFO) is a common atrial septal defect that is largely asymptomatic and often undiagnosed. The impact of aPFOin patients undergoing liver transplantation (LT) is unknown.ObjectiveAssess the impact ofPFOand physiologic intrapulmonary shunt (IPS) on the perioperative outcomes of patients who underwentLT.MethodsWe performed a retrospective, intention‐to‐treat analysis of patients withPFOand controls withoutPFOwho underwentLTat Mayo Clinic in Florida between 2008 and 2013. Patients with physiologicIPSwere also analyzed. The cohorts were compared for baseline characteristics, length of stay in the intensive care unit (ICU), postoperative oxygen requirements, 30‐d cerebrovascular accidents, and mortality.ResultsOf the 935 patients who underwentLT, 10.4% had provenPFOby pre‐LTechocardiogram. Control patients (n = 101) were statistically older thanPFOandIPS(n = 56) patients, but similar in sex,BMI, Model for End‐stage Liver Disease score, American Society of Anesthesiologist score, and left ventricular ejection fraction.PFOandIPSpatients had similar length of stay in theICU, mechanical ventilation times, post‐LToxygen requirements, and 30‐d mortality compared to controls. Subgroup analysis showed similar outcomes for largePFOandIPSpatients to controls.ConclusionsThe presence ofPFOdid not have a negative impact on perioperativeLToutcomes.
A novel objective method for deceased donor and recipient size matching in liver transplantation
Croome, Kristopher P. , Lee, David D. , Saucedo‐Crespo, Hector , Burns, Justin M. , Nguyen, Justin H. , Perry, Dana K. , Taner, C. Burcin , Croome, Kris P , Lee, David D

Mayo Clinic

Liver Transplantation | September 11, 2015 | Volume: 21 | Issue: 12 | Pages: 1471-1477

10.1002/lt.24333 | PMID 26358746 Get It

Although the consequences of implantation of a large whole liver graft into a small recipient such as compression and compromise of graft perfusion are well known, no accepted measure to aid in donor‐to‐recipient size matching exists. Donor liver graft and recipient native liver weights as well as donor and recipient size and amount of ascites were investigated in 1953 patients who underwent liver transplantation using deceased donor grafts between January 2002 and July 2013. We used a previously described formula for liver resections (standardized total liver volume [sTLV] = –794.41 + 1267.28 × body surface area [m2]) for calculating sTLV, in the current cohort of deceased liver donors. Early allograft dysfunction (EAD) and graft survival were the primary outcome measures. The formula for calculating sTLV for liver resections was validated as an accurate predictor of liver volume in the current cohort of deceased liver donors (r2 = 0.45;P < 0.001). A cutoff point of sTLV ratio ≥ 1.25 was determined through receiver operating characteristic curves, and patients were dichotomized into 2 groups. In the sTLV ratio ≥ 1.25 group, 50% of patients developed EAD compared to 25% of patients in the sTLV ratio < 1.25 group (P < 0.001). The proportion of patients developing graft failure within 90 days was 9.6% in the sTLV ratio ≥ 1.25 group and 5.4% in the sTLV ratio < 1.25 group (P = 0.045). This study validates the use of the sTLV for prediction of actual donor liver weight in the transplant setting. Using this formula, donors with a calculated sTLV size ratio ≥ 1.25 have an increased risk of EAD and therefore caution should be used when that value is exceeded. This adjusted size ratio can be used as a decision aid when considering donor and recipient matching with potential liver organ offers.Liver Transpl 21:1471‐1477, 2015. © 2015 AASLD.
Intracardiac thrombosis during liver transplant: A 17‐year single‐institution study
Peiris, Prith, Pai, Sher‐Lu , Aniskevich, Stephen , Crawford, Claudia C. , Torp, Klaus D. , Ladlie, Beth L., Shine, Timothy, Nguyen, Justin H. , Shine, Timothy S, Taner, C. Burcin , Pai, Sher-Lu , Aniskevich, Stephen

Mayo Clinic

Liver Transplantation | May 4, 2015 | Volume: 21 | Issue: 10 | Pages: 1280-1285

10.1002/lt.24161 | PMID 25939618 Get It

Intracardiac thrombosis (ICT) during orthotopic liver transplantation (OLT) is an uncommon event. However, it is a devastating complication with high mortality when it occurs. This study aimed to identify possible predisposing factors for ICT during OLT. We retrospectively identified the cases of all patients with ICT during OLT at our institution from 1998 to 2014. Of 2750 OLTs performed, 10 patients had ICT intraoperatively. The patients' immediate prethrombosis intraoperative hemodynamic and coagulation values and thromboelastography (TEG) data were reviewed. Preexisting venous thrombosis, atrial fibrillation, and the prior placement of a transjugular intrahepatic portosystemic shunt for portal hypertension were noted in several patients and may be related to ICT during OLT. A high Model of End‐Stage Liver Disease score, low cardiac output, and sepsis did not appear to be associated with ICT. ICT occurred in some patients without the administration of antifibrinolytic agents. TEG and coagulation parameters did not appear to be helpful in predicting the onset of ICT. Four patients had ICT in both right‐ and left‐sided heart chambers; none of these 4 patients survived. All 6 patients with only right‐sided thrombus survived. In those who survived, improved hemodynamics and clot disappearance on transesophageal echocardiography (TEE) occurred over time, even without the use of thrombolytics. Whether this is because of endogenous thrombolysis or distal clot propagation into the pulmonary vasculature, or both, is unclear. Tissue plasminogen activator may have a role in the resuscitation procedure. In conclusion, without the routine use of TEE during OLT, the incidence of ICT will remain an under‐recognized event. Liver Transpl 21:1280‐1285, 2015. © 2015 AASLD.
Preexisting atrial fibrillation and cardiac complications after liver transplantation
Bargehr, Johannes , Trejo-Gutiérrez, Jorge F. , Rosser, Barry, Aranda‐Michel, Jaime, Yataco, Maria, Patel, Tushar , Rosser, Barry G., Taner, C. Burcin

Mayo Clinic

Liver Transplantation | December 9, 2014 | Volume: 21 | Issue: 3 | Pages: 314-320

10.1002/lt.24060 | PMID 25488693 Get It

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and it is associated with increased cardiovascular morbidity and all‐cause mortality. Our aim was to determine the impact of preexisting AF on patients undergoing liver transplantation (LT). A retrospective case‐control study was performed. Records from patients who underwent LT between January 2005 and December 2008 at Mayo Clinic Florida were reviewed. Patients with preexisting AF were identified and matched to patients who did not have a diagnosis of AF. Thirty‐two of 717 LT recipients (4.5%) had AF before LT. These patients were compared to a control group of 63 LT recipients. Pre‐LT left ventricular hypertrophy (P = 0.03), a history of congestive heart failure (P = 0.04), and a history of stroke or transient ischemic attack (P = 0.03) were significantly more prevalent in patients with AF versus controls. Intraoperative adverse cardiac events (P = 0.02) and AF‐related adverse postoperative events (P < 0.001) were more common in the recipients with known AF. Six patients with paroxysmal AF (19%) developed chronic/persistent AF postoperatively. Graft survival and patient survival were similar in the groups. Although patients with AF had a higher incidence of intraoperative cardiac events, a higher cardiovascular morbidity rate, and a complicated postoperative course, this did not affect overall graft and patient survival. Liver Transpl 21:314–320, 2015. © 2014 AASLD.
Reversible non‐ischaemic cardiomyopathy and left ventricular dysfunction after liver transplantation: a single‐centre experience
Yataco, Maria, Difato, Thomas, Bargehr, Johannes , Rosser, Barry G., Patel, Tushar , Trejo-Gutiérrez, Jorge F. , Pungpapong, Surakit , Aranda‐Michel, Jaime, Yataco, Maria L, Taner, C. Burcin , Patel, Tushar , Pungpapong, Surakit

Mayo Clinic

Liver International | February 17, 2014 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/liv.12501 | PMID 24529030 Get It

AbstractBackground & AimsNon‐ischaemic cardiomyopathy (NIC) is an early complication of liver transplantation (LT). Our aims were to define the prevalence, associated clinical factors, and prognosis of this condition.MethodsA retrospective study was performed on patients undergoingLTat our institution from January 2005 to December 2012. Patients who developedNICwere identified. Data collected included demographic and clinical data.ResultsA total 1460 transplants were performed in this period and seventeen patients developedNIC. Pretransplant medianQTc interval was 459 (range, 405–530), and median E/A ratio was 1 (range, 0.71–1.67). Fourteen patients (82%) were severely malnourished and required nutritional support. Thirteen patients (76%) had renal insufficiency. Median time to onset was 2 days post‐transplant (range, 0–20). Echocardiograms showed global left ventricular hypokinesis and a decrease in ejection fraction (EF) from a median of 65% (range, 50–81) pretransplant to a median of 21% (range, 15–32). Median raw model for end‐stage liver disease (MELD) score was 29 in patients withNICvs. 18 in patients without cardiomyopathy (P = 0.01). There was no significant difference between recipients withNICvs. recipients without cardiomyopathy regarding donor age, donor risk index, and cold and warm ischaemia time. Recovery of cardiac function occurred in 16 patients, with a medianEFof 44% (range, 25–65%) at the time of discharge. The last echocardiogram available showed a medianEFof 59% (range, 49–73%). One‐year survival of NIC patients was 94.1%.ConclusionNon‐ischaemic cardiomyopathy is a rare complication afterLT. Patients withNICare critically ill, with highMELDscore, and severe malnutrition.
Agonal period in donation after cardiac death donors
Bulatao, Ilynn , Perry, Dana K. , Sibulesky, Lena , Wllingham, Darrin L., Kramer, David J., Nguyen, Justin H. , Taner, C. Burcin

Mayo Clinic

Transplant International | February 14, 2013 | Volume: 26 | Issue: 3 | Pages: e17-e18

10.1111/tri.12056 | PMID 23405915 Get It